{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Magrangeas F"],"funding":["NCI NIH HHS","PHS HHS"],"pagination":["473-81"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4157227"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(2)"],"pubmed_abstract":["Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent relapse in multiple myeloma (MM). This issue was addressed in a cohort of 24 MM patients treated either with conventional chemotherapy or with the proteasome inhibitor, bortezomib. As MM is a highly heterogeneous disease associated with a large number of chromosomal abnormalities, a subset of secondary genetic events that seem to reflect progression, 1q21 gain, NF-κB-activating mutations, RB1 and TP53 deletions, was examined. By using high-resolution single-nucleotide polymorphism arrays, subclones were identified with nonlinear complex evolutionary histories. Such reordering of the "],"journal":["Leukemia"],"pubmed_title":["Minor clone provides a reservoir for relapse in multiple myeloma."],"pmcid":["PMC4157227"],"funding_grant_id":["P01-78378","P01 CA155258-01","R01-124929","P01 CA155258","P50 CA100707","P01 CA078378","P50-100007"],"pubmed_authors":["Garderet L","Voog E","Casassus P","Moreau P","Lode L","Marit G","Hulin C","Gouraud W","Anderson KC","Tiab M","Randriamalala E","Decaux O","Munshi NC","Godmer P","Voillat L","Stoppa AM","Avet-Loiseau H","Facon T","Magrangeas F","Minvielle S"],"additional_accession":[]},"is_claimable":false,"name":"Minor clone provides a reservoir for relapse in multiple myeloma.","description":"Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent relapse in multiple myeloma (MM). This issue was addressed in a cohort of 24 MM patients treated either with conventional chemotherapy or with the proteasome inhibitor, bortezomib. As MM is a highly heterogeneous disease associated with a large number of chromosomal abnormalities, a subset of secondary genetic events that seem to reflect progression, 1q21 gain, NF-κB-activating mutations, RB1 and TP53 deletions, was examined. By using high-resolution single-nucleotide polymorphism arrays, subclones were identified with nonlinear complex evolutionary histories. Such reordering of the ","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Feb","modification":"2026-04-29T07:58:35.625Z","creation":"2025-07-02T03:05:36.542Z"},"accession":"S-EPMC4157227","cross_references":{"pubmed":["22874878"],"doi":["10.1038/leu.2012.226"]}}